MB and COVID-19: The pronounced cytolytic syndrome in the patients who developed AKI (Group A), demonstrated by elevated serum values for myoglobin, LDH, and CK, may represent a mechanistic contributor to AKI in COVID-19, beyond being a marker of disease severity.